Mechanisms of platelet retention in the collagen-coated-bead column

Journal of Laboratory and Clinical Medicine

Volumn 142, Issue 4, 2003, Pages 258-267

  Kaneko, Makoto ^b   Cuyun Lira, Olga ^b   Takafuta, Toshiro ^b   Suzuki Inoue, Katsue ^b   Satoh, Kaneo ^b   Ohtsuki, Kayoko ^b   Ohnishi, Masatoshi ^b   Arai, Morio ^b   Yatomi, Yutaka ^b   Ozaki, Yukio ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; ARGATROBAN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PROSTACYCLIN DERIVATIVE; VON WILLEBRAND FACTOR;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HUMAN; PROTEIN INTERACTION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

EID: 0344083557     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00133-1     Document Type: Article

References (52)

1. Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001;86:178-88.
2. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, et al. A revised model of platelet aggregation. J Clin Invest 2000;105:783-91.
3. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
4. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 1973;5:167-79.
5. Baumgartner HR, Haudenschild C. Adhesion of platelets to subendothelium. Ann N Y Acad Sci 1972;201:22-36.
6. Salzman EW. Measurement of platelet adhesiveness. A simple in vitro technique demonstrating an abnormality in von Willebrand's disease. J Lab Clin Med 1963;62:724-35.
7. Hellem AJ. Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method. Scand J Haematol 1970;7:374-82.
8. Roper-Drewinko PR, Drewinko B, Corrigan G, Johnston D, McCredie KB, Freireich EJ. Standardization of platelet function tests. Am J Hematol 1981;11:183-203.
9. Rossi EC, Green D. A study of platelet retention by glass bead columns ('platelet adhesiveness' in normal subjects). Br J Haematol 1972;23:47-57.
10. Carr ME Jr. In vitro assessment of platelet function. Transfusion Med Rev 1997;11:106-15.
11. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-63.
12. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-44.
13. Favaloro EJ. Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder. Best Pract Res Clin Haematol 2001;14:299-319.
14. Eto K, Isshiki T, Yamamoto H, Takeshita S, Ochiai M, Yokoyama N, et al. AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 1999;19:877-82.
15. Suzuki-Inoue K, Ozaki Y, Kainoh M, Shin Y, Wu Y, Yatomi Y, et al. Rhodocytin induces platelet aggregation by interacting with glycoprotein Ia/IIa (GPIa/IIa, Integrin alpha 2beta 1). Involvement of GPIa/IIa-associated src and protein tyrosine phosphorylation. J Biol Chem 2001;276:1643-52.
16. Romijn RA, Bouma B, Wuyster W, Gros P, Kroon J, Sixma JJ, et al. Identification of the collagen-binding site of the von Willebrand factor A3-domain. J Biol Chem 2001;276:9985-91.
17. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997;99:1467-71.
18. Arai M, Yamamoto N, Moroi M, Akamatsu N, Fukutake K, Tanoue K. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol 1995;89:124-30.
19. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998;94:657-66.
20. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001;86:189-97.
21. Goto S, Tamura N, Handa S, Arai M, Kodama K, Takayama H. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 2002;106:266-72.
22. Moroi M, Jung SM, Shinmyozu K, Tomiyama Y, Ordinas A, Diaz-Ricart M. Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Blood 1996;88:2081-92.
23. Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. Embo J 2001;20:2120-30.
24. Weiss HJ. Flow-related platelet deposition on subendothelium. Thromb Haemost 1995;74:117-22.
25. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997;95:860-7.
26. Sakakibara M, Goto S, Eto K, Tamura N, Isshiki T, Handa S. Application of ex vivo flow chamber system for assessment of stent thrombosis. Arterioscler Thromb Vasc Biol 2002;22:1360-4.
27. Ofosu FA. The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences. Biochemistry (Mosc) 2002;67:47-55.
28. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol 1994;31:261-9.
29. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968;47:2169-80.
30. Watson SP, Ruggiero M, Abrahams SL, Lapetina EG. Inositol 1,4,5-trisphosphate induces aggregation and release of 5-hydroxytryptamine from saponin-permeabilized human platelets. J Biol Chem 1986;261:5368-72.
31. Weiss HJ. Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med 1975;293:531-41.
32. Weksler BB. Antiplatelet agents in stroke prevention. Combination therapy: present and future. Cerebrovasc Dis 2000;10:41-8.
33. Kitai T, Nishikawa M, Tanigawa T, Okinaka T, Wada H, Shiku H, et al. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease. Am Heart J 2001;142: E1.
34. Goto S, Tamura N, Sakakibara M, Ikeda Y, Handa S. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation. Platelets 2001;12:406-14.
35. Storey F. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 2001;12:197-209.
36. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-7.
37. Gachet C. Identification, characterization, and inhibition of the platelet ADP receptors. Int J Hematol 2001;74:375-81.
38. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86:222-32.
39. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107:1591-8.
40. Knofler R, Weissbach G, Kuhlisch E. Release of adenosine triphosphate by adenosine diphosphate in whole blood and in erythrocyte suspensions. Am J Hematol 1997;56:259-65.
41. McPherson J, Zucker MB. Platelet retention in glass bead columns: adhesion to glass and subsequent platelet-platelet interactions. Blood 1976;47:55-67.
42. Alkhamis TM, Beissinger RL, Chediak JR. Artificial surface effect on red blood cells and platelets in laminar shear flow. Blood 1990;75:1568-75.
43. Santoro SA. Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell 1986;46:913-20.
44. Shadle PJ, Barondes SH. Adhesion of human platelets to immobilized trimeric collagen. J Cell Biol 1982;95:361-5.
45. Satoh K, Asazuma N, Yatomi Y, Fujimura Y, Miura S, Titani K, et al. Activation of protein-tyrosine kinase pathways in human platelets stimulated with the A1 domain of von Willebrand factor. Platelets 2000;11:171-6.
46. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
47. Frelinger AL 3rd, Hillman RS. Novel methods for assessing platelet function. Am Heart J 1998;135:S184-6.
48. Qi R, Ozaki Y, Satoh K, Kurota K, Asazuma N, Yatomi Y, et al. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin. Thromb Res 1996; 81:43-54.
49. Kondo K, Seo R, Naka M, Kitagawa T, Wakitani K, Sakata M, et al. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis. Eur J Pharmacol 1989;163:253-61.
50. Remijn JA, Wu YP, Jeninga EH, Ijsseldijk MJ, van Willigen G, de Groot PG, et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002;22:686-91.
51. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001;98: 3340-5.
52. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6.